Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSGeneric

REDITREX

METHOTREXATE

Standard Dose
20MG/0.8ML (20MG/0.8ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview REDITREX is listed in Drugs@FDA under application 210737 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient METHOTREXATE Form and strength SOLUTION;SUBCUTANEOUS - 20MG/0.8ML (20MG/0.8ML) Sponsor NORDIC GRP Submission history Latest submission status date: 2023-03-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview REDITREX is listed in Drugs@FDA under application 210737 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient METHOTREXATE Form and strength SOLUTION;SUBCUTANEOUS - 20MG/0.8ML (20MG/0.8ML) Sponsor NORDIC GRP Submission history Latest submission status date: 2023-03-30 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
REDITREX (METHOTREXATE) | Drug Monograph | MedicHelpline